Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

Bio2RDF uri

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00614731

Bio2RDF identifier

NCT00614731

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00614731

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

Atopic dermatitis (AD) ...... e vaccines to people with AD.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Responses to Immunization With ...... tion and the Intradermal Route

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:a5e5a008cfaedc75cd568ff8ef27aa3a]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:fb572471973c251b267e83251fa5c04f]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:06d64ad3b115357dd9a09c8e368e8736]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:434364590b2f2bf3b44ef2861b7c056c]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:6263081642a7f027a4631fb729d035da]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:71907fdffbf0911f36e3996ef42bb826]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:ba7ba6777988b2c3cfb79c44ae38945b]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:ec769e00a32557e2250020cc9fe911c0]

Change in anti-KLH IgG antibody response to two vaccinations of KLH in nonatopic participants At baseline and Day 47 [clinicaltrials_resource:f34019fcce81ecc5200862cf10e12e2c]

collaborator [clinicaltrials_vocabulary:collaborator]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

completion date [clinicaltrials_vocabulary:completion-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Atopic Dermatitis [clinicaltrials_resource:d2b87e3914bc2def6d8cb17856e8d5d3]

condition browse [clinicaltrials_vocabulary:condition-browse]

Eczema [clinicaltrials_resource:2e5a2294002b179551c2a7cde1813525]

Dermatitis, Atopic [clinicaltrials_resource:73d919b1d112d02de4a57a76bd5be95c]

Dermatitis [clinicaltrials_resource:f3898163355388a4d9c3a8a19b300964]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Eczema [clinicaltrials_resource:2e5a2294002b179551c2a7cde1813525]

Dermatitis, Atopic [clinicaltrials_resource:73d919b1d112d02de4a57a76bd5be95c]

Dermatitis [clinicaltrials_resource:f3898163355388a4d9c3a8a19b300964]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

AD is characterized by ...... d blood and urine collection.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00614731 [clinicaltrials_resource:c4349ed2963c66c9aa9e4afa08ce337a]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2008-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

KLH carrier-protein [clinicaltrials_resource:7feda7acde102ca2fc002d08ff3b3eb6]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Keyhole-limpet hemocyanin [clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

IgG antibodies

http://www.w3.org/2001/XMLSchema#string

KLH

http://www.w3.org/2001/XMLSchema#string

Keyhole Limpet Hemocyanin

http://www.w3.org/2001/XMLSchema#string

atopic dermatitis

http://www.w3.org/2001/XMLSchema#string

scarification

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

location [clinicaltrials_vocabulary:location]

National Jewish Health [clinicaltrials_resource:bd4dd66d7a01ab488d6a6283a5ac2d2a]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00614731

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Responses to Immunization With ...... tion and the Intradermal Route

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

DAIT ADVN KLH 07

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Henry Milgrom, M.D. [clinicaltrials_resource:d4f4ee17076ec23f4f52cad25f6ad097]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

Contract No. HHSN266200400029C

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

start date [clinicaltrials_vocabulary:start-date]

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00614731 study design [clinicaltrials_resource:6118b2da61049ac4c4d9a03b45d9c7c2]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00614731

verification date [clinicaltrials_vocabulary:verification-date]

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00614731

http://www.w3.org/2001/XMLSchema#string

title

Responses to Immunization With ...... tion and the Intradermal Route

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3